clinical trial · NCT07553663
Evaluating the Pharmacokinetics and Safety of Miricorilant
Nonalcoholic Steatohepatitis (NASH)Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated CirrhosisMetabolic Dysfunction-associated Steatotic Liver Disease (MASLD)Non-alcoholic Fatty Liver Disease (NAFLD)Miricorilant
brief summary
A Phase 1b, Open-Label Study Evaluating the Pharmacokinetics and Safety of Miricorilant in Adult Patients With Presumed Metabolic Dysfunction-Associated Steatohepatitis (MASH)
started
Apr 30, 2026
primary completion
Oct 30, 2026
completion
Oct 30, 2026
last updated
Apr 28, 2026
detailed description
Approximately 15 patients who are eligible for participation in the study will be administered a single dose of 60 mg of miricorilant. The maximum expected duration of a patient's participation is 56 days (up to 28 days of screening, followed by single-dose administration and 4 days of observation, and then 24 days of follow-up).
official title
A Phase 1b, Open-Label Study Evaluating the Pharmacokinetics and Safety of Miricorilant in Adult Patients With Presumed Metabolic Dysfunction-Associated Steatohepatitis (MASH)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol